Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I

[1]  S. Adami,et al.  Involvement of WNT/β-catenin Signaling in the Treatment of Osteoporosis , 2013, Calcified Tissue International.

[2]  L. Idolazzi,et al.  Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  L. Idolazzi,et al.  Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. , 2012, Bone.

[4]  Joan C. Marini,et al.  New perspectives on osteogenesis imperfecta , 2011, Nature Reviews Endocrinology.

[5]  L. Idolazzi,et al.  The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. , 2011, The Journal of clinical endocrinology and metabolism.

[6]  Hang Lee,et al.  Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.

[7]  Hironori Ito,et al.  Bisphosphonate Therapy for Osteogenesis Imperfecta , 2009 .

[8]  F. Glorieux,et al.  Osteogenesis Imperfecta: Update on presentation and management , 2008, Reviews in Endocrine and Metabolic Disorders.

[9]  S. Boonen,et al.  Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. , 2008, The Journal of clinical endocrinology and metabolism.

[10]  Matthew R Allen,et al.  Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin* , 2008, Journal of Biological Chemistry.

[11]  R. Baron,et al.  Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. , 2007, Endocrinology.

[12]  M. Rubin,et al.  The use of parathyroid hormone in the treatment of osteoporosis , 2007, Reviews in Endocrine and Metabolic Disorders.

[13]  P. Kostenuik,et al.  Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. , 2006, Bone.

[14]  S. Adami,et al.  Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. , 2006, The Journal of pediatrics.

[15]  S. Ott.  Sclerostin and Wnt signaling--the pathway to bone strength. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  A. Schott,et al.  Effects of Oral Alendronate on BMD in Adult Patients With Osteogenesis Imperfecta: A 3‐Year Randomized Placebo‐Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  L. Tatò,et al.  Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  S. Adami,et al.  Bone turnover markers in patients with osteogenesis imperfecta. , 2004, Bone.

[19]  S. Adami,et al.  The volumetric bone density and cortical thickness in adult patients affected by osteogenesis imperfecta. , 2003, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[20]  S. Adami,et al.  Intravenous Neridronate in Adults With Osteogenesis Imperfecta , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[22]  D. Galas,et al.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.

[23]  K. Dwan,et al.  Bisphosphonate therapy for osteogenesis imperfecta. , 2014, The Cochrane database of systematic reviews.